Top Abstract Purchase Related
Home
>
Node
>
Subnode

Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer

Shore, N.D.; Sieber, P.; Schimke, L.; Perzin, A.; Olsen, S.

Urologic Nursing 33(5): 236-44 248

2013

ISSN/ISBN: 1053-816X
PMID: 24354113
Document Number: 668383
This multicenter, randomized, crossover, open-label study (ClinicalTrials.gov identifier: NCT01161563) assessed patients'and clinicians'perceptions of injection site tolerability and adverse events following the intramuscular injection of triptorelin pamoate or subcutaneous injection of leuprolide acetate in 107 male, patients with advanced prostate cancer.

Document emailed within 1 workday
Secure & encrypted payments

Wei, A.Y.; Mijal, K.A.; Christianson, M.S.; Schouweiler, C.M.; Lindheim, S.R. 2008: Comparison of GnRH antagonists and flareup GnRH agonists in donor oocyte cycles Journal of Reproductive Medicine 53(3): 147-150
Fiore, A.Patricia.Perez.; Fragoso, Y.Dadalti. 2005: Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months Arquivos de Neuro-Psiquiatria 63(3b): 738-740
Suzumura, T.; Kimura, T.; Kudoh, S.; Umekawa, K.; Nagata, M.; Tanaka, H.; Mitsuoka, S.; Yoshimura, N.; Kira, Y.; Hirata, K. 2012: Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population Osaka City Medical Journal 58(1): 25-34
Abbou, C.C.; Lucas, C.; Leblanc, V. 1997: Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(6): 984-995
Fitzpatrick, J.M. 1996: Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument against European Urology 29(Suppl): 37-39
Koinuma, N.; Takeyoshi, H. 2003: Economic analysis of adverse events in cancer treatment Nihon Rinsho. Japanese Journal of Clinical Medicine 61(6): 1030-1038
Hori, J.; Wada, N.; Tamaki, G.; Azumi, M.; Kita, M.; Iwata, T.; Matsumoto, S.; Kakizaki, H. 2016: Combination of GnRH Antagonist Degarelix and Antiandrogen Is Effective in PSA Reduction and Bone Management in Patients with Prostate Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 43(6): 727-731
See, H.T.; Koo, W.H.; Ang, P.; Au, E.; Ang, P.T. 2002: Efficacy and tolerability of irinotecan in patients with advanced colorectal cancer in Singapore Annals of the Academy of Medicine Singapore 31(5): 651-655
Espaulella, J.; Armengol, J.; Bella, F.; Lain, J.M.; Calaf, J. 1991: Pulmonary endometriosis: conservative treatment with GnRH agonists Obstetrics and Gynecology 78(3 Part 2): 535-537
Hemmings, R. 1998: Combined treatment of endometriosis. GnRH agonists and laparoscopic surgery Journal of Reproductive Medicine 43(3 Suppl): 316-320
Tanimoto, A.; Yano, S. 2015: Notable adverse events of ALK inhibitors in patients with ALK rearranged non-small-cell lung cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 73 Suppl. 2: 256-260
Stromberg, J.S.; Martinez, A.A.; Horwitz, E.M.; Gustafson, G.S.; Gonzalez, J.A.; Spencer, W.F.; Brabbins, D.S.; Dmuchowski, C.F.; Hollander, J.B.; Vicini, F.A. 1997: Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment Cancer Journal from Scientific American 3(6): 346-352
Ivanov, S.; Ivanov, S. 1998: The use of Ovestin to overcome the side effects of treatment with GnRH agonists (Zoladex) Akusherstvo i Ginekologiia 37(4): 25-26
Campusano, C.; Zapata, R.; Bianchi, M.; Badia, J.I.; Arteaga, E. 1993: Usefulness of GnRH agonists in preoperative treatment of complicated uterine myomata Revista Chilena de Obstetricia y Ginecologia 58(2): 150-154
Bezruchka, S. 2001: Adverse events in British hospitals. Expanded definition of adverse events is needed Bmj 322(7299): 1427
Orovan, W.L. 1989: Treatment of advanced cancer of the prostate Canadian Journal of Surgery. Journal Canadien de Chirurgie 32(5): 315-316
Faris, G.; Stein, A.; Lurie, A. 1993: Hormonal treatment of advanced prostate cancer Harefuah 124(1): 35-40
Wechsel, H.W.; Zerbib, M.; Pagano, F.; Coptcoat, M.J. 1996: Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer European Urology 30(Suppl): 7
Kurokawa, K.; Suzuki, K.; Yamanaka, H. 2003: Treatment strategy for locally advanced prostate cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(1): 38-42
Azuma, H.; Katsuoka, Y. 2006: Treatment for locally advanced prostate cancer: value of surgery Hinyokika Kiyo. Acta Urologica Japonica 52(6): 459-467